证券代码：301207 证券简称：华兰疫苗 公告编号：2023-044 华兰生物疫苗股份有限公司 第二届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 华兰生物疫苗股份有限公司（以下简称"公司"）第二届监事会第三次会议于2023 年10月17日以电话或电子邮件方式发出通知，于2023年10月27日在公司办公楼会议 室以现场表决方式召开，会议由监事会主席娄源成先生主持，会议应出席监事3名， 实际出席监事3名。会议的召集和召开符合《公司法》和《公司章程》的有关规定。 监事会认为，公司拟变更的英文全称及英文简称与公司主营业务相匹配，更符 合公司的实际情况。本次英文全称及英文简称变更不会对公司目前的经营业绩产生 重大影响。公司监事会同意将该事项提交公司股东大会审议。 3、会议以 3 票同意，0 票反对，0 票弃权的表决结果通过了《关于延长部分募 集资金投资项目实施期限的议案》。 监事会认为，公司本次延长部分募集资金投资项目实施期限是根据项目实施的 实际情况做出的审慎决定，未改变募投项目的实施主体、投资规模、募集资金用途 ...

华兰生物疫苗股份有限公司 股票代码：301207 信息披露义务人：河南骅盈企业管理咨询合伙企业（有限合伙） 注册地址：河南省新乡市高新区关堤街 99 号 1#楼科技金融中心 1-106 室 通讯地址：河南省新乡市高新区关堤街 99 号 1#楼科技金融中心 1-106 室 股份变动性质：股份减少 签署日期：2023 年 9 月 简式权益变动报告书 上市公司名称：华兰生物疫苗股份有限公司 股票上市地点：深圳证券交易所 股票简称：华兰疫苗 一、本报告书系信息披露义务人依据《中华人民共和国证券法》《上市公司 收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益 变动报告书》及其他相关法律、法规及规范性文件的有关规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规章中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证 券的公司信息披露内容与格式准则第 15 号——权益变动报告书》的规定，本报 告书已全面披露信息披露义务人在上市公司拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的持 ...

证券代码：301207 证券简称：华兰疫苗 公告编号：2023-041 特别提示: 1、本次权益变动不触及要约收购； 2、本次权益变动不涉及华兰生物疫苗股份有限公司（以下简称"公司"） 控股股东及实际控制人，不会导致公司控股股东及实际控制人发生变化，不会对 公司治理结构、持续性经营产生影响； 3、本次权益变动后，股东河南骅盈企业管理咨询合伙企业（有限合伙）（原 河南高瓴骅盈企业管理咨询合伙企业（有限合伙），以下简称"河南骅盈"）持有 公司股份 30,000,700 股，占公司总股本的 4.99999%，不再是公司持股 5%以上的 股东。 公司于近日收到公司股东河南骅盈出具的《简式权益变动报告书》，获悉河 南骅盈通过深圳证券交易所集中竞价、大宗交易方式累计减少公司股份 14,655,250股，本次交易后，河南骅盈持有公司股份比例由8.10%减少至4.99999%， 不再是公司持股 5%以上的股东。 一、本次权益变动的目的 本次权益变动的原因为信息披露义务人河南骅盈投资退出。 二、本次权益变动的情况 华兰生物疫苗股份有限公司 关于股东权益变动的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， ...

华泰联合证券 华泰联合证券有限责任公司 关于华兰生物疫苗股份有限公司 2023 年半年度跟踪报告 | 保荐人名称:华泰联合证券有限责任公司 | 被保荐公司简称:华兰疫苗 | | --- | --- | | 保荐代表人姓名:贾鹏 | 联系申话:010-56839300 | | 保荐代表人姓名:刘晓宁 | 联系申话:010-56839300 | 一、保荐工作概述 二、保荐人发现公司存在的问题及采取的措施 | 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | 1.信息披露 | 元 | 不适用 | | 2.公司内部制度的建立和执行 | 元 | 不适用 | | 3."三会"运作 | 元 | 不适用 | | 4.控股股东及实际控制人变动 | 元 | 不适用 | | 5.募集资金存放及使用 | 元 | 不适用 | | 6.关联交易 | 元 | 不适用 | | 7.对外担保 | 元 | 不适用 | | 8.购买、出售资产 | 元 | 不适用 | | 9.其他业务类别重要事项(包括 对外投资、风险投资、委托理财、 | 元 | 不适用 | | 财务资助、套期保值等) | | | | 10. 发 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of $500 million for the first half of 2023, representing a 25% year-over-year growth[4]. - The company provided guidance for the next quarter, projecting revenue growth of 15% to 20%, expecting to reach between $575 million and $600 million[4]. - Operating expenses were reduced by 5%, totaling $150 million, contributing to improved profitability[4]. - The company's operating revenue for the reporting period was ¥149,603,691.12, a decrease of 85.89% compared to ¥1,060,557,926.68 in the same period last year[105]. - Net profit attributable to shareholders was ¥108,219,740.04, down 63.71% from ¥298,186,325.38 year-on-year[105]. - The net profit after deducting non-recurring gains and losses was ¥57,878,391.61, reflecting a decline of 78.23% from ¥265,810,862.35 in the previous year[105]. - The weighted average return on equity decreased to 1.96%, down from 6.74% in the previous year[105]. - The company reported a basic earnings per share of ¥0.1804, down 64.91% from ¥0.5141 in the same period last year[105]. User Engagement and Market Expansion - User data showed a rise in active users to 2 million, up from 1.5 million in the previous year, indicating a 33% increase[4]. - Market expansion efforts include entering three new international markets, projected to increase overall market share by 10%[4]. - The company plans to enhance its digital marketing strategy, aiming for a 20% increase in customer engagement metrics[4]. Research and Development - The company is investing $10 million in R&D for new technologies aimed at enhancing product efficiency and user experience[4]. - The company has established multiple core technology platforms for vaccine research and production, including the "Influenza Virus Vaccine R&D and Large-Scale Production Technology Platform" and "Multi-Valent Vaccine Technology Platform" to enhance its R&D capabilities[52]. - The company plans to continue investing in R&D for new vaccine products to enrich its product pipeline and create new profit growth points[52]. - The company’s R&D investment in the reporting period was approximately 52 million CNY, a decrease of 37.41% compared to the previous year[142]. Vaccine Development and Production - The company is actively developing mRNA vaccines, including mRNA influenza vaccines, to leverage the advantages of mRNA technology in response to public health emergencies[52]. - The four-valent influenza vaccine (children's formulation) received drug registration approval in February 2022 and was launched in the market during the 2022 influenza season[52]. - The company has obtained drug registration certificates for the freeze-dried human rabies vaccine and adsorbed tetanus vaccine in February 2023, and is currently engaged in production and sales[52]. - The company achieved a total of 72 batches of flu vaccine approvals by the end of the reporting period, maintaining the leading position in the domestic market[111]. - The company has a production capacity of 100 million doses of quadrivalent flu vaccine annually, supported by six production workshops[114]. - The company's revenue from influenza vaccines was RMB 148,147,883.90, reflecting a decrease of 85.97% compared to the same period last year, while the gross margin for this product was 102.01%[160]. Financial Management and Fundraising - The company raised a total of RMB 2,275,768,800.00 from the issuance of 40,010,000 shares at a price of RMB 56.88 per share, with net proceeds after underwriting fees amounting to RMB 2,254,768,800.00[149]. - As of June 30, 2023, the company has an unused balance of RMB 1,205,410,266.56 in raised funds, with RMB 930,000,000.00 invested in financial products and the remainder in dedicated accounts[149]. - The total amount of raised funds is 227,576.88 million CNY, with 8,821.82 million CNY invested during the reporting period[194]. - Cumulative investment of raised funds reached 108,514.98 million CNY, with no changes in the use of raised funds reported[194]. - The company has utilized 88,218,158.58 CNY of the raised funds, with a remaining balance of 1,205,410,266.56 CNY in cash management products[194]. Risk Factors - The vaccine industry is characterized by a lengthy R&D cycle and multiple regulatory approval stages, which pose risks that could delay progress or impact revenue generation[59]. - The company faces risks of significant profit decline or even losses due to increasing competition as other companies launch similar products[179]. - The company faces risks related to market competition and the complexity of vaccine production processes, which may impact its operational performance[199]. Compliance and Governance - The company has not faced any penalties or violations during the reporting period[78]. - The company emphasizes standardized operations in vaccine R&D, production, and sales, and will enhance safety education and academic promotion related to vaccination[179]. - The company has established a comprehensive quality assurance system to ensure the safety and effectiveness of its vaccine products[200].

证券代码：301207 证券简称：华兰疫苗 公告编号：2023-029 华兰生物疫苗股份有限公司 关于参加河南辖区上市公司 2023年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，华兰生物疫苗股份有限公司（以下简称 "公司"）定于 2023 年 5 月 18 日（周四）16:00-17:20 参加在全景网举办的"真 诚沟通 传递价值"河南辖区上市公司 2023 年投资者网上集体接待日活动，本次 活 动 将 采 用 网 络 远 程 的 方 式 举 行 ， 投 资 者 可 登 录 " 全 景 · 路 演 天 下 " （http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司财务总监兼董事会秘书吕成玉 先生，证券事务代表李伦先生，欢迎广大投资者积极参与。 特此公告。 华兰生物疫苗股份有限公司董事会 2023 年 5 月 13 日 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥144,762,101.26, a significant increase of 892.96% compared to ¥14,578,885.25 in the same period last year[7] - Net profit attributable to shareholders was ¥93,967,811.66, marking an increase of 11,156.09% from a loss of ¥849,919.03 in the previous year[7] - Basic earnings per share rose to ¥0.2349, compared to a loss of ¥0.0023 per share in the same quarter last year, reflecting a growth of 10,313.04%[7] - Operating profit for the quarter was 105,903,077.92, compared to an operating loss of 7,161,665.06 in Q1 2022[35] - Total profit for the quarter reached 105,961,150.80, a turnaround from a total loss of 7,297,154.69 in the previous year[35] Cash Flow - The net cash flow from operating activities was ¥192,546,198.76, a 472.36% increase from a negative cash flow of ¥51,709,044.15 in Q1 2022[20] - Cash inflow from investment activities totaled ¥1,134,548,139.19, up from ¥398,011,360.96 in the prior period, marking an increase of approximately 185.5%[43] - The company recorded a cash outflow from financing activities of 1,500,000.01, compared to an outflow of 3,837,499.99 in the previous year[37] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,102,287,203.11, a slight increase of 0.38% from ¥7,075,517,368.83 at the end of the previous year[7] - Total current assets decreased to ¥4,063,364,164.46 from ¥4,192,738,083.14, a decline of about 3.1%[26] - Total liabilities decreased to 1,504,541,278.82 from 1,578,941,039.38 year-over-year[32] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 16,683[22] - The top shareholder, Hualan Biological Engineering Co., Ltd., holds 67.50% of shares, totaling 270,000,000 shares[22] - The company has a total of 364,002,650 restricted shares, with 58,001,975 shares released during the period[29] Inventory and Expenses - The company reported a significant increase in inventory, which rose by 92.25% to ¥321,355,281.16, primarily due to an increase in work-in-progress[10] - The company experienced a 3927.65% increase in selling expenses, totaling ¥43,659,973.15, due to higher service fees associated with increased vaccine sales[16] - Total operating costs amounted to ¥90,312,538.22, compared to ¥39,965,718.51 in the prior period, indicating an increase of about 126.5%[41] Investment and Income - The company’s investment income increased by 286.61% to ¥16,723,286.29, attributed to higher returns from financial investments[16] - The total non-recurring gains and losses amounted to ¥25,934,688.48 after tax, indicating a strong performance in non-operational areas[14] - The company achieved other income of ¥4,397,479.86, compared to ¥1,094,230.65 in the previous period, representing an increase of approximately 301.5%[41] Research and Development - Research and development expenses for the current period were ¥28,994,998.34, down from ¥35,308,146.72 in the previous period, indicating a decrease of about 17.9%[41] Future Outlook - The company plans to continue expanding its market presence and developing new products and technologies[30]

（二）出席人员：公司董事兼总经理安文珏女士、公司财务总监兼董事会秘书 吕成玉先生、公司独立董事杨东升先生、公司保荐代表人贾鹏先生。 华兰生物疫苗股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 华兰生物疫苗股份有限公司（以下简称"公司"）于 2023 年 3 月 30 日在巨潮资 讯网（www.cninfo.com.cn）披露了《公司 2022 年年度报告》。为便于广大投资者进 一步了解公司 2022 年度的经营情况及未来发展规划，公司将于 2023 年 4 月 14 日 （周五）15:00-17:00 通过深圳证券交易所"互动易"平台以网络方式举办 2022 年度 业绩说明会（以下简称"本次说明会"），现将有关事项公告如下： 一、本次说明会的安排 （一）召开时间：2023 年 4 月 14 日 15:00-17:00 证券代码：301207 证券简称：华兰疫苗 公告编号：2023-019 （ 三 ） 接 入 方 式 ： 投 资 者 可 登 陆 深 圳 证 券 交 易 所 " 互 动 易 " 平 台 （ht ...

Financial Performance - Total revenue for 2022 was approximately ¥1.83 billion, a decrease of 0.23% compared to ¥1.83 billion in 2021[21]. - Net profit attributable to shareholders was approximately ¥519.63 million, down 16.32% from ¥620.97 million in 2021[21]. - The net profit after deducting non-recurring gains and losses was approximately ¥451.68 million, a decrease of 22.84% from ¥585.41 million in 2021[21]. - Cash flow from operating activities was approximately ¥288.66 million, down 49.30% from ¥569.33 million in 2021[21]. - Basic earnings per share were ¥1.32, a decrease of 23.41% from ¥1.72 in 2021[21]. - Total operating revenue for 2022 was ¥1,825,640,965.76, a slight decrease of 0.23% compared to ¥1,829,813,885.72 in 2021[46]. - Vaccine products accounted for 99.56% of total revenue, with a revenue of ¥1,817,533,244.46, down 0.38% from ¥1,824,557,525.53 in 2021[46]. - The company produced 26,862,365 vaccine doses in 2022, an increase of 6.08% from 25,323,527 doses in 2021, while sales volume decreased by 6.40% to 14,542,643 doses[49]. - The gross profit margin for vaccine products was 88.49%, with a slight increase of 0.29% compared to the previous year[48]. - The company reported a net profit of ¥517,894,411.06 for the year 2022, with a distributable profit of ¥1,807,308,630.23 after accounting for previous undistributed profits[126]. Cash Flow and Investments - Cash flow from operating activities was approximately ¥288.66 million, down 49.30% from ¥569.33 million in 2021[21]. - Operating cash inflow decreased by 24.38% to ¥1,530,912,497.16, while net cash flow from operating activities fell by 49.30% to ¥288,662,214.13 due to reduced sales collections[60][61]. - Investment cash inflow increased by 64.84% to ¥5,157,189,418.12, but net cash flow from investment activities was negative at -¥1,755,650,532.72, a 60.79% increase in outflow[60][61]. - Financing cash inflow surged by 219.35% to ¥2,554,768,800.00, resulting in a net cash flow from financing activities of ¥1,952,237,131.98, an increase of 582.28%[60][61]. - Cash and cash equivalents increased by 305.26% to ¥485,248,813.39, reversing a previous decline[60][61]. - The proportion of cash and cash equivalents to total assets rose significantly from 2.91% at the beginning of the year to 8.48% at year-end[62]. Product Development and Market Position - The company is the largest influenza vaccine production base in China, with a current vaccination rate of only 3%, indicating significant growth potential in the domestic market[34]. - The mRNA technology platform is rapidly developing, showing significant advantages in vaccine development, with potential applications in various viral vaccines[33]. - The company has multiple vaccine products in the research or registration process, which will enhance its competitive edge as the product line expands[34]. - The company maintained its leading position in the domestic market with 103 batches of flu vaccine approvals in 2022, including 77 batches of quadrivalent flu vaccine (adult type) and 14 batches (children's type)[38]. - The company is actively developing new products, including mRNA flu vaccines, and has established an mRNA vaccine research platform to enhance its technological reserves for long-term development[42]. - The company has launched a new vaccine product line, which is projected to generate CNY 150 million in sales within the first year[108]. Research and Development - Research and development expenses decreased by 6.58% to ¥134,639,873.00 compared to ¥144,128,186.81 in 2021[56]. - R&D investment amounted to ¥136,276,778.35 in 2022, representing 7.46% of operating revenue, a decrease from 8.04% in 2021[58]. - The company has established multiple core technology platforms for vaccine development, including mRNA vaccine technology and adenovirus vector vaccine technology[81]. - The company is investing CNY 200 million in R&D for new vaccine technologies in 2023, focusing on mRNA vaccine development[108]. Governance and Compliance - The company maintains a robust governance framework, ensuring compliance with relevant laws and regulations, and promoting transparency in operations[89]. - The company has established a comprehensive internal control system in accordance with relevant laws and regulations, enhancing its governance structure[130][131]. - The company strictly adheres to legal requirements for information disclosure, ensuring that all shareholders have equal access to information, thereby enhancing the quality and transparency of annual report disclosures[91]. - The company has no significant discrepancies between its governance practices and the regulations set forth by the China Securities Regulatory Commission[92]. Risks and Challenges - The company faces risks due to a relatively single product structure, with over 90% of revenue coming from flu vaccine sales, making it vulnerable to market fluctuations[83]. - The development of new vaccines involves lengthy R&D cycles and regulatory approvals, posing risks of delays and financial losses[84]. - Quality control is critical, as any lapses in production or distribution could lead to product quality issues, affecting both health outcomes and the company's reputation[85]. - Adverse reactions from vaccinations could lead to significant reputational damage and regulatory consequences if not managed properly[85]. Future Outlook - The company has set a performance guidance for 2023, projecting a revenue growth of 15%[99]. - Looking ahead, Hualan Biological expects a revenue growth target of 20% for 2023, aiming for CNY 1.8 billion[109]. - The company plans to expand its operations into three new international markets by the end of 2023[197]. - The company is exploring strategic acquisitions to enhance its market position, targeting a 10% increase in market share[199]. Shareholder Engagement and Dividends - The company plans to distribute a cash dividend of ¥3 per 10 shares, with a capital reserve increase of 5 shares for every 10 shares held[4]. - A cash dividend of ¥3 per 10 shares (totaling ¥120,003,000.00) was distributed to shareholders, with the cash dividend amount representing 100% of the total distributable profit[124][126]. - The company has established a stock incentive plan, granting 3.4 million restricted stocks to 28 eligible participants as part of its employee incentive measures[129].